Human umbilical cord-derived mesenchymal stem cells ameliorate non-alcoholic fatty liver disease via activating TFEB-mediated autophagy in male mice
Open Access
- 13 December 2025
- journal article
- research article
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by abnormal lipid accumulation in hepatocytes and defective autophagy has been implicated in its pathogenesis. Human umbilical cord-derived MSCs (hUC-MSCs) have shown therapeutic potential in treating NAFLD, while underlying molecular mechanisms remained largely unknown. Methods: Male C57BL/6J mice fed a choline-deficient high fat diet (CD-HFD) and HepG2 cells exposed to palmitic acid/oleic acid were established as in vivo and in vitro models of NAFLD, respectively. Both models were subjected to treatment with human umbilical cord-derived MSCs (hUC-MSCs). Lipid content, proinflammatory cytokines, fibrosis markers and the hepatic transcriptome were assessed to determine the effect of hUC-MSCs. Results: Here, hUC-MSCs decreased hepatic lipid content and alanine aminotransferase/aspartate aminotransferase levels, as well as attenuated inflammation and fibrosis in choline-deficient high-fat diet (CD-HFD)-induced NAFLD mice. Mechanistically, hUC-MSCs restored impaired autophagic flux and mitigated liver steatosis through the AMPK-mTOR-TFEB pathway in both NAFLD mice and oleic acid/palmitic acid-induced “fatty” HepG2 cells. Of note, hUC-MSCs have been found to promote nuclear translocation of TFEB in PA/OA-induced HepG2 cells. Additionally, TFEB knockdown partially attenuated the effect of hUC-MSCs on enhancing autophagy and lipid metabolism in vitro. Conclusions: This study suggests that hUC-MSCs represent a potential therapeutic approach to treating NAFLD through activating TFEB-mediated autophagy.Keywords
Funding Information
- Noncommunicable Chronic Diseases-National Science and Technology Major Project (2025ZD0549900)
- the Natural Science Foundation of China (82070913)
- Shanghai Science and Technology Development Funds (22410713200)
- Key discipline project of Hongkou District Health Commission (HKLCFC202403)
- the Fund of Shanghai Hongkou District Health Committee (Hong Wei 2303-06)
- Research fund from Shanghai Fourth People’s Hospital (sykyqd01801,SY-XKZT-2021-1001)
This publication has 77 references indexed in Scilit:
- The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver diseaseHepatology International, 2025
- Extracellular vesicles derived from bone marrow mesenchymal stem cells ameliorate liver fibrosis via micro-7045-5pMolecular and Cellular Biochemistry, 2024
- Human umbilical cord mesenchymal stem cells attenuate diet-induced obesity and NASH-related fibrosis in miceHeliyon, 2024
- Mesenchymal stem cells-derived exosomal miR-24-3p ameliorates non-alcohol fatty liver disease by targeting Keap-1Biochemical and Biophysical Research Communications, 2022
- Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate experimental non-alcoholic steatohepatitis via Nrf2/NQO-1 pathwayFree Radical Biology and Medicine, 2022
- Human umbilical cord-derived mesenchymal stem cell-exosomal miR-627-5p ameliorates non-alcoholic fatty liver disease by repressing FTO expressionHuman Cell, 2021
- Therapeutic regulation of autophagy in hepatic metabolismActa Pharmaceutica Sinica B, 2021
- Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathwayFree Radical Biology and Medicine, 2019
- Compact bone-derived mesenchymal stem cells attenuate nonalcoholic steatohepatitis in a mouse model by modulation of CD4 cells differentiationInternational Immunopharmacology, 2017
- Expanding Roles for SREBP in MetabolismCell Metabolism, 2012